18 results
Thumbnail

- D3.147 - The inhaled PDE4 inhibitor tanimilast shows a broad anti-inflammatory effect in two mouse models of asthma induced by house dust mite

Thumbnail

- D3.148 - Oscillometry and spirometry derived ratios to assess small airways dysfunction in severe asthma patients taking tezepelumab

Thumbnail

D3.149 - Worse airflow obstruction but not type 2 biomarkers identifies super-responders to tezepelumab in a real life clinic setting

Thumbnail

- D3.150 - Effects of benralizumab on T cell adhesion molecules in severe eosinophilic asthma: modulation by IL-25 and IL-33

Thumbnail

- D3.151 - Prevalence and clinical characteristics of adult asthma patients with different phenotype across GINA step 1 to 5 asthma

Thumbnail

D3.152 - Phenotype and treatment response of allergic patients with severe asthma: a real-world experience from Argentina

Thumbnail

- D3.154 - Safety of allergen immunotherapy in patients with severe asthma. A real-world, multicentre, observational retrospective study

Thumbnail

D3.155 - IL-1 signaling pathway molecules as key markers in childhood severe asthma

Thumbnail

- D3.156 - Self-reported asthma symptoms and asthma medication usage in patients with possible asthma: A MASK-air® real-world study

Thumbnail

D3.157 - A study of the detailed patterns of wheeze presence and absence from infancy through to adolescence

Thumbnail

- D3.158 - Clinical and functional profile of children with asthma in a tertiary referral hospital

Thumbnail

D3.159 - Investigation of Huai Qi Huang Granules' Impact and Mechanism on Asthmatic Mice's Antiviral Capability

Thumbnail

- D3.162 - The Effects of Phthalate Exposure on Asthma via Microbiota Changes

Thumbnail

- D3.163 - Mast cell activation test and airway hyperresponsiveness in cat allergy: investigating the link to cat allergen induced asthma

Thumbnail

D1.149 - Murine IgG1 increased y subcutaneous immunotherapy suppressed development of allergic asthma

Thumbnail

D1.150 - Study design for the saFety assessment of an Accelerated up-dosing scheme using one Strength of a native house dust mite allergen extract for subcutaneous immunoTherapy in children with allergic asthma in China (FAST II study)

Thumbnail

D1.153 - Protocol for a randomized, 5-arm study to evaluate the combination of omalizumab and allergen immunotherapy in patients with asthma due to house dust mites

Thumbnail

D1.154 - Safety of ultra-rush immunotherapy starting protocol with the molecular extract Diater Alt a 1 mol mix